Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma

Glioblastoma multiforme (GBM) is a lethal disease characterized by an overall survival of about 1 year, making it one of the most aggressive tumours, with very limited therapeutic possibilities. Specific biomarkers for early diagnosis as well as innovative therapeutic strategies are urgently needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Dufrusine, Beatrice, Capone, Emily, Ponziani, Sara, Lattanzio, Rossano, Lanuti, Paola, Giansanti, Francesco, De Laurenzi, Vincenzo, Iacobelli, Stefano, Ippoliti, Rodolfo, Mangiola, Annunziato, Trevisi, Gianluca, Sala, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399712/
https://www.ncbi.nlm.nih.gov/pubmed/37195369
http://dx.doi.org/10.1002/1878-0261.13453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399712/
https://www.ncbi.nlm.nih.gov/pubmed/37195369
http://dx.doi.org/10.1002/1878-0261.13453

Ejemplares similares